A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

B. F. El-Rayes, M. Zalupski, T. Bekai-Saab, L. K. Heilbrun, N. Hammad, B. Patel, S. Urba, A. F. Shields, U. Vaishampayan, S. Dawson, K. Almhanna, D. Smith, P. A. Philip

Research output: Contribution to journalArticle

86 Scopus citations

Abstract

Background: Bevacizumab has demonstrated antitumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction. Patients and methods: Previously untreated patients with locally advanced or metastatic disease and a performance status (PS) of 0-1 were eligible for this study. Patients received bevacizumab at 7.5 mg/kg, docetaxel at 70 mg/m2, and oxaliplatin at 75 mg/m2 administered on day 1 of a 21-day cycle. The primary end point of the study was progression-free survival (PFS). Results: A total of 38 eligible patients (median age 57 years, 45% gastric, 55% PS 0) were enrolled on to the study. Median PFS was 6.6 months [95% confidence interval (CI) 4.4-10.5] and median survival 11.1 months (95% CI 8.2-15.3). Complete responses were documented in 2 (5%) patients, partial responses in 14 (37%), and stable disease in 14 (37%). No treatment-related deaths were observed. The most commonly reported grade 3-4 toxicity was neutropenia (34%), and gastrointestinal perforation occurred in three patients (8%). Conclusion: The combination of bevacizumab, docetaxel, and oxaliplatin has promising activity for further evaluation in randomized trials.

Original languageEnglish (US)
Pages (from-to)1999-2004
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number10
DOIs
StatePublished - Mar 23 2010

Keywords

  • Bevacizumab
  • Docetaxel
  • Gastric cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers'. Together they form a unique fingerprint.

  • Cite this

    El-Rayes, B. F., Zalupski, M., Bekai-Saab, T., Heilbrun, L. K., Hammad, N., Patel, B., Urba, S., Shields, A. F., Vaishampayan, U., Dawson, S., Almhanna, K., Smith, D., & Philip, P. A. (2010). A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Annals of Oncology, 21(10), 1999-2004. https://doi.org/10.1093/annonc/mdq065